DDrare: Database of Drug Development for Rare Diseases

5. 進行性核上性麻痺
［臨床試験数：82，薬物数：107（DrugBank：36），標的遺伝子数：60，標的パスウェイ数：90］

Searched query = "Progressive supranuclear palsy", "PSP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 18F-AV-1451; 18F-FDG; 18F-RO6958948; 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione; AB1010; ABBV-8E12; AL; AL-108; ASK Nr. 21972; AZP2006 oral solution; Alpha-lipoic acid and L-acetyl carnitine; Anti-Parkinson medication; Antisense oligonucleotide; Azilect; BIIB092; BMS-986168; BMS986168; BOTULINUM TOXIN TYPE A; Balance; Bepranemab; Botulinum toxin type A; Carnitine; CoQ10; Coenzym Q10 Nanodispersion; Coenzym Q10, Ubiquinon, Ubichinon; Coenzyme Q10; Creatine; DaTSCAN™ Ioflupane (123I) Injection; DaTscan; Datscan; Davunetide; Davunetide (AL-108, NAP); Device: Deep Brain Stimulation; Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau; Diagnostic Test: Flutemetamol F18 Injection; Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau; Diagnostic Test: [18F]-RO6958948; Donepezil; Droxidopa; Emeramide; Exelon 1,5 mg Hartkapseln; Exelon 3,0 mg Hartkapseln; Exelon 6,0 mg Hartkapseln; F-18; F-18 AV 1451; Flortaucipir; Flortaucipir F18; Flutemetamol; Flutemetamol F18; Fresh Frozen Plasma; GDNF & Synchro Med Infusion System; Gold; Hydrogen; Leucine; Lipoic acid; Lithium; MASITINIB MESYLATE; Masitinib; Masitinib 100mg; Masitinib 200mg; Masitinib mesylate; N1,N3-BIS(2-MERCAPTOETHYL) ISOPHTHALAMIDE; NBMI; NP031112; NP031112 600mg; NP031112 800mg; NT 101; Niacinamide; Nitrogen; Other: 13C6 Leucine; Placebo; Procedure: Brain PET scan; Pyruvate, creatine, niacinamide; RASAGILINE MESILATE; RIVASTIGMINE; Raclopride; Radiopharmaceuticals; Rasagilin; Rasagiline; Riluzole; Rivastigmine; Salsalate; Single dose C2N-8E12; Stem cell therapy; Sugar pill; Suvorexant; TPI 287 2 mg/m2; TPI-287 20 mg/m2; TPI-287 6.3 mg/m2; Tideglusib; Tolfenamic Acid; Tolfenamic acid; Trihexyphenidyl; UCB0107 (bepranemab); Ubidecarenon; Valproic acid; Vizamyl; Vizamyl (flutemetamol(F-18)); Water; Xeomin; Zolpidem; [18F]Florbetapir; [18F]MNI-815 (MNI-815); [18F]MNI-952; [18F]MNI-958; [18F]T807 ([18F]MNI-777); [F18]-FDDNP

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2006-006166-42-DE (EUCTR)	17/07/2007	02/01/2007	Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese -offene, prospektive Phase II-Studie -	Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese -offene, prospektive Phase II-Studie -	Progressive supranuclear palsy (PSP) is a neurodegenerative disorder with hardly any therapeutical option to ameliorate the course of the disease. Results of first trials with physostigmine and donepezil did not point out a definite benefit. In contrast, first clinical observations concerning an effect with rivastigmine in PSP with dementia were promising. This may be due to the fact, that rivastigmine excerts a double action inhibiting both the acetylcholin- and the buturylcholinesterase.	Trade Name: Exelon 1,5 mg Hartkapseln INN or Proposed INN: RIVASTIGMINE Trade Name: Exelon 3,0 mg Hartkapseln INN or Proposed INN: RIVASTIGMINE Trade Name: Exelon 6,0 mg Hartkapseln INN or Proposed INN: RIVASTIGMINE	University of Tuebingen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2-	Germany
2	NCT00139373 (ClinicalTrials.gov)	May 2005	30/8/2005	Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy	Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy	Supranuclear Palsy, Progressive	Drug: donepezil	Groupe Hospitalier Pitie-Salpetriere	Institut National de la Santé Et de la Recherche Médicale, France	Recruiting	30 Years	80 Years	Both	16	Phase 2	France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2006-006166-42-DE
(EUCTR)

17/07/2007

02/01/2007

Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese -offene, prospektive Phase II-Studie -

Progressive supranuclear palsy (PSP) is a neurodegenerative disorder with hardly any therapeutical option to ameliorate the course of the disease. Results of first trials with physostigmine and donepezil did not point out a definite benefit. In contrast, first clinical observations concerning an effect with rivastigmine in PSP with dementia were promising. This may be due to the fact, that rivastigmine excerts a double action inhibiting both the acetylcholin- and the buturylcholinesterase.

Trade Name: Exelon 1,5 mg Hartkapseln
INN or Proposed INN: RIVASTIGMINE
Trade Name: Exelon 3,0 mg Hartkapseln
INN or Proposed INN: RIVASTIGMINE
Trade Name: Exelon 6,0 mg Hartkapseln
INN or Proposed INN: RIVASTIGMINE

University of Tuebingen

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2-

Germany

NCT00139373
(ClinicalTrials.gov)

May 2005

30/8/2005

Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy

Supranuclear Palsy, Progressive

Drug: donepezil

Groupe Hospitalier Pitie-Salpetriere

Institut National de la Santé Et de la Recherche Médicale, France

Recruiting

30 Years

80 Years

Both

Phase 2

France